MAPT and Alzheimer disease: Specifically, relationships with amyloid and cognition are relatively inconsistent [43–45], and accumulating evidence suggests that changes in cognition in the preclinical stages of AD are predominantly driven by tau pathology and structural changes, rather than by amyloid alone [41, 46, 47].